Promotion of Rat Hepatocarcinogenesis by Praziquantel

Overview

Journal Jpn J Cancer Res

Specialty Oncology

Date 1991 Oct 1

PMID 1683346

Authors

T Shirai

K D Joong

K Hakoi

W Thamavit

C Pairojkul

T Hoshiya

R Hasegawa

N Ito

Affiliations

Soon will be listed here.

Abstract

Praziquantel, the widely used anti-helminthic agent, was investigated for hepatocarcinogenesis-promoting potential using a medium-term liver bioassay system for carcinogens. F344 male rats were given a single intraperitoneal injection of diethylnitrosamine (DEN, 200 mg/kg) and then starting 2 weeks later, received praziquantel in the diet at concentrations of 1.5 or 0.5%, or intragastrically at a dose of 1,500 mg/kg once a week for 6 weeks. Control groups received DEN or praziquantel alone. All rats were subjected to two-thirds partial hepatectomy at week 3 and killed at week 8. Development of glutathione S-transferase placental form-positive foci in the liver was significantly increased in terms of both number and area with the 1.5% dose, while only area was affected by the 0.5% dose. The results thus indicate that praziquantel at high dose has promoting potential in rat hepatocytic tumorigenesis.

References

Evans H, Bourgeois C, Comer D, Keschamras N . Biliary tract changes in opisthorchiasis. Am J Trop Med Hyg. 1971; 20(5):667-71. DOI: 10.4269/ajtmh.1971.20.667. View

Ito N, Tatematsu M, Hasegawa R, Tsuda H . Medium-term bioassay system for detection of carcinogens and modifiers of hepatocarcinogenesis utilizing the GST-P positive liver cell focus as an endpoint marker. Toxicol Pathol. 1989; 17(4 Pt 1):630-41. DOI: 10.1177/0192623389017004108. View

Thamavit W, Bhamarapravati N, Sahaphong S, VAJRASTHIRA S, Angsubhakorn S . Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res. 1978; 38(12):4634-9. View

Kurathong S, Lerdverasirikul P, Wongpaitoon V, Pramoolsinsap C, Kanjanapitak A, Varavithya W . Opisthorchis viverrini infection and cholangiocarcinoma. A prospective, case-controlled study. Gastroenterology. 1985; 89(1):151-6. DOI: 10.1016/0016-5085(85)90755-3. View

Bhamarapravati N, Thammavit W, VAJRASTHIRA S . Liver changes in hamsters infected with a liver fluke of man, Opisthorchis viverrini. Am J Trop Med Hyg. 1978; 27(4):787-94. DOI: 10.4269/ajtmh.1978.27.787. View

Thamavit W, Kongkanuntn R, Tiwawech D, Moore M . Level of Opisthorchis infestation and carcinogen dose-dependence of cholangiocarcinoma induction in Syrian golden hamsters. Virchows Arch B Cell Pathol Incl Mol Pathol. 1987; 54(1):52-8. DOI: 10.1007/BF02899196. View

Bhamarapravati N, Virranuvatti V . Liver diseases in Thailand. An analysis of liver biopsies. Am J Gastroenterol. 1966; 45(4):267-75. View

Billings P, HEIDELBERGER C . Effects of praziquantel, a new antischistosomal drug, on the mutation and transformation of mammalian cells. Cancer Res. 1982; 42(7):2692-6. View

Bartsch H, Kuroki T, Malaveille C, Loprieno N, Barale R, Abbondandolo A . Absence of mutagenicity of praziquantel, a new, effective, anti-schistosomal drug, in bacteria, yeasts, insects and mammalian cells. Mutat Res. 1978; 58(2-3):133-42. DOI: 10.1016/0165-1218(78)90002-2. View

10.

Thamavit W, Moore M, Hiasa Y, Ito N . Enhancement of DHPN induced hepatocellular, cholangiocellular and pancreatic carcinogenesis by Opisthorchis viverrini infestation in Syrian golden hamsters. Carcinogenesis. 1988; 9(6):1095-8. DOI: 10.1093/carcin/9.6.1095. View

11.

Bunnag D, Pungpark S, Harinasuta T, Viravan C, Vanijanonta S, Suntharasamai P . Opisthorchis viverrini: clinical experience with praziquantel in Hospital for Tropical Diseases. Arzneimittelforschung. 1984; 34(9B):1173-4. View

12.

FROHBERG H . Results of toxicological studies on praziquantel. Arzneimittelforschung. 1984; 34(9B):1137-44. View

13.

Obermeier J, FROHBERG H . Mutagenicity studies with praziquantel, a new anthelmintic drug: tissue-, host-, and urine-mediated mutagenicity assays. Arch Toxicol. 1977; 38(3):149-61. DOI: 10.1007/BF00293649. View

14.

Upatham E, Viyanant V, Kurathong S, Brockelman W, Menaruchi A, Saowakontha S . Morbidity in relation to intensity of infection in Opisthorchiasis viverrini: study of a community in Khon Kaen, Thailand. Am J Trop Med Hyg. 1982; 31(6):1156-63. DOI: 10.4269/ajtmh.1982.31.1156. View

15.

Machemer L, Lorke D . Mutagenicity studies with praziquantel, a new anthelmintic drug, in mammalian systems. Arch Toxicol. 1978; 39(3):187-97. DOI: 10.1007/BF00368227. View

16.

King C, Mahmoud A . Drugs five years later: praziquantel. Ann Intern Med. 1989; 110(4):290-6. DOI: 10.7326/0003-4819-110-4-290. View

17.

HARINASUTA C, Harinasuta T . Opisthorchis viverrini: life cycle, intermediate hosts, transmission to man and geographical distribution in Thailand. Arzneimittelforschung. 1984; 34(9B):1164-7. View

18.

Bunyaratvej S, Meenakanit V, Tantachamrun T, Srinawat P, Susilaworn P, Chongchitnan N . Nationwide survey of major liver diseases in Thailand analysis of 3 305 biopsies as to year-end 1978. J Med Assoc Thai. 1981; 64(9):432-9. View

19.

Ketkar M, ALTHOFF J, Mohr U . A chronic study of praziquantel in Syrian golden hamsters and Sprague-Dawley rats. Toxicology. 1982; 24(3-4):345-50. DOI: 10.1016/0300-483x(82)90016-6. View

20.

Batzinger R, Ou S, Bueding E . Antimutagenic effects of 2(3)-tert-butyl-4-hydroxyanisole and of antimicrobial agents. Cancer Res. 1978; 38(12):4478-85. View